Ryuichi Mizuno

Nivolumab plus Cabozantinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Toni K. Choueiri, Thomas Powles, Mauricio Burotto et al. · New England Journal of Medicine · 2021 · 1.6K citations · Full text

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 627 citations · Full text

First-line Therapy, Urology, Chemotherapy Versus Chemotherapy +7

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for clear cell renal cell carcinoma (KEYNOTE-564): 30-month follow-up analysis of a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

Thomas Powles, Piotr Tomczak, Se Hoon Park et al. · The Lancet Oncology · 2022 · 262 citations · Full text

B7–H3 Ligand Expression by Primary Breast Cancer and Associated With Regional Nodal Metastasis

Takaaki Arigami, Norihiko Narita, Ryuichi Mizuno et al. · Annals of Surgery · 2010 · 146 citations

Increased nuclear factor-κB activation is related to the tumor development of renal cell carcinoma

Mototsugu Oya, Atsushi Takayanagi, Akio Horiguchi et al. · Carcinogenesis · 2003 · 128 citations · Full text

Renal Pathology, Immunology, Pathology +17